Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical’s CEO, Dr. Steven Gourlay, delivered a presentation at the Dementia Trials Australia Annual Scientific Meeting, discussing promising phase 2a trial results of Xanamem in treating depression and its potential efficacy in Alzheimer’s disease. Xanamem aims to control brain cortisol levels, offering a new approach to therapy for Alzheimer’s and depression, with further studies anticipated on other neurological conditions. The company is currently conducting a Phase 2b trial for Alzheimer’s, with interim results expected in 2025.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
